Table 4.
Maximum slope and bolus arrival time according to invasive cancer characteristics
| No. of lesions† | Maximum slope (mmol/s) | Bolus arrival time (s) | |||||
|---|---|---|---|---|---|---|---|
| Median | IQR | P value | Median | IQR | P value | ||
| Tumor grade | 111 | 0.552 | 0.025* | ||||
| Grade 3 | 56 (50) | 0.034 | 0.022–0.054 | 21.3 | 19.3–23.4 | ||
| Grade 1 or 2 | 55 (50) | 0.026 | 0.015–0.045 | 22.5 | 20.8–25.2 | ||
| Histopathology | 118 | 0.133 | 0.002* | ||||
| IDC | 98 (83) | 0.030 | 0.019–0.054 | 21.6 | 19.6–23.6 | ||
| ILC | 20 (17) | 0.028 | 0.013–0.049 | 23.7 | 21.8–25.9 | ||
| Molecular subtype | 124 | 0.361 | < 0.001* | ||||
| HER2+ type or triple negative type | 33 (27) | 0.049 | 0.028–0.059 | 19.9 | 17.9–22.3 | ||
| Luminal type | 91 (73) | 0.027 | 0.017–0.045 | 22.5 | 20.7–24.8 | ||
| Lymph node metastasis status | 121 | 0.467 | 0.714 | ||||
| Positive | 57 (47) | 0.030 | 0.016–0.051 | 21.9 | 20.2–23.8 | ||
| Negative | 64 (53) | 0.030 | 0.022–0.055 | 21.9 | 19.7–23.8 | ||
| Oncotype DX recurrence score | 45 | 0.538 | 0.633 | ||||
| High/intermediate risk | 15 (33) | 0.032 | 0.025–0.049 | 22.2 | 20.2–24.7 | ||
| Low risk | 30 (67) | 0.026 | 0.015–0.046 | 21.7 | 20.4–23.7 | ||
MS maximum slope, BAT bolus arrival time, IQR interquartile range, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma
*P < 0.05
†Data in parentheses are percentages
‡Molecular subtype are classified as follows: triple negative type [hormone receptor negative, HER2 negative], HER2 type [HER2 positive regardless of the hormone receptor positivity/negativity], or luminal type [hormone receptor positive, HER2 negative]